Tags: Drug.
Lixivaptan (VPA-985) is a phase III pharmaceutical being developed by Cardiokine Inc. a specialty pharmaceutical company based in Philadelphia PA focused on the development of pharmaceuticals for the treatment and prevention of cardiovascular diseases. Lixivaptan is as of May 2010 in Phase III clinical trials involving patients with hyponatremia including those with concomitant heart failure.
